ARRY - Based on the trial description there was no crossover but the endpoint was changed more than a year after the trial began.
Which begs the question of what statistical impact, if any, that had on OS HR. What if OS had remained as a secondary endpoint all along? Would we have had a better HR for OS?
News 
Market Data 
Discover 
